Live Analyst Rating Changes 3274 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/James Vane
JEF
James Vane
Jefferies
Wall Street Analyst
★★★★★
#24
on 13Foresight · ranked by our own returns
75%
Success Rate
+81.8%
Average Return
3 of 4 calls profitable · +92.7% vs benchmark
📈 Across the calls we could measure, roughly 75% of James Vane's ratings turned a profit when each position was held for 1 year — averaging +81.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

47 Buy 28 Hold 9 Sell
James's Stock Coverage 38 ratings · 2026-06-27
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
DE:MRK
Merck KGaA
 Jun 25, 2026 HOLD Buy
-6.6% avg upside
33 analysts
$129.00
11.48% Downside
 ·
RGEDF
Chemical Works of Gedeon Richter
 Jun 12, 2026 BUY Strong Buy
+4.8% avg upside
3 analysts
$47.27
19.32% Upside
 ·
CH:NOVN
Novartis AG
 Jun 11, 2026 HOLD Buy
-15.1% avg upside
31 analysts
$110.00
12.88% Downside
 ·
GB:OXB
Oxford BioMedica
 Jun 02, 2026 BUY Strong Buy
+57.7% avg upside
4 analysts
$827.00
30.57% Upside
 ·
ES:ROVI
Laboratorios Farmaceuticos Rovi
 May 13, 2026 HOLD Hold
+9.6% avg upside
1 analyst
$64.20
9.60% Upside
 ·
CH:SFZN
Siegfried Holding AG
 May 13, 2026 HOLD Hold
+30.9% avg upside
3 analysts
$88.00
25.63% Upside
 ·
CH:LONN
Lonza Group Ltd
 May 13, 2026 BUY Strong Buy
+19.6% avg upside
20 analysts
$762.00
42.63% Upside
 ·
DE:SHL
Siemens Healthineers AG
 May 07, 2026 BUY Buy
+52.3% avg upside
23 analysts
$60.00
75.35% Upside
 ·
DE:FRE
Fresenius SE & Co. KGaA
 May 06, 2026 BUY Strong Buy
+28.2% avg upside
20 analysts
$55.00
38.12% Upside
 ·
DE:FME
Fresenius Medical Care AG & Co. KGaA
 May 05, 2026 SELL Hold
+24.6% avg upside
22 analysts
$31.00
24.13% Downside
 ·
CH:SDZ
Sandoz Group Ltd
 May 05, 2026 BUY Buy
-8.4% avg upside
11 analysts
$84.00
16.88% Upside
 ·
GB:HIK
Hikma Pharmaceuticals
 May 05, 2026 BUY Strong Buy
+52.1% avg upside
8 analysts
$1870.00
22.08% Upside
 ·
DE:SRT3
Sartorius
 Apr 23, 2026 BUY Strong Buy
+22.7% avg upside
18 analysts
$307.00
37.00% Upside
 ·
PL:DIA
Diagnostyka S.A.
 Apr 21, 2026 HOLD Hold
1 analyst
$188.00
 ·
DE:SRT
Sartorius
 Mar 18, 2026 BUY Strong Buy
+103.6% avg upside
5 analysts
$246.00
33.55% Upside
 ·
FR:DIM
Sartorius Stedim Biotech
 Mar 17, 2026 BUY Strong Buy
+42.8% avg upside
11 analysts
$262.00
49.50% Upside
 ·
IT:1SXP
SCHOTT Pharma AG & Co. KGaA
 Feb 11, 2026 HOLD Hold
+14.0% avg upside
6 analysts
$15.50
10.18% Downside
 ·
DE:GXI
Gerresheimer
 Feb 02, 2026 BUY Buy
+133.1% avg upside
15 analysts
$34.10
31.43% Upside
 ·
NL:PHIA
Koninklijke Philips N.V.
 Jan 16, 2026 HOLD Buy
+29.4% avg upside
21 analysts
 — ·
GB:CVSG
CVS Group plc
 Oct 29, 2025 HOLD Buy
+30.3% avg upside
4 analysts
$1420.00
20.25% Upside
 ·
FR:VIRP
Virbac SA
 Oct 22, 2025 HOLD Hold
+5.5% avg upside
4 analysts
$368.00
7.58% Upside
 ·
CH:BANB
Bachem Holding AG
 Sep 25, 2025 SELL Strong Sell
+2.5% avg upside
4 analysts
$49.30
31.51% Downside
 ·
GB:SPI
Spire Healthcare
 Aug 15, 2025 BUY Strong Buy
+35.5% avg upside
6 analysts
$298.00
37.23% Upside
 ·
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
 Aug 11, 2025 BUY Buy
-6.6% avg upside
7 analysts
$61.50
19.41% Upside
 ·
INDV
Indivior
 Feb 25, 2025 BUY Strong Buy
-14.3% avg upside
10 analysts
$12.86
69.17% Downside
 +307.1%
FMS
Fresenius Medical Care
 Aug 08, 2024 SELL Hold
+83.1% avg upside
14 analysts
$17.50
24.66% Downside
 -35.7%
FSNUY
Fresenius SE & Co
 May 14, 2024 BUY Strong Buy
-8.1% avg upside
7 analysts
$11.00
3.61% Downside
 +50.1%
FR:CLARI
Clariane
 Jan 05, 2024 HOLD Buy
+402.4% avg upside
6 analysts
$4.49
6.24% Upside
 ·
CH:STMN
Straumann Holding AG
 Feb 23, 2023 BUY Buy
+20.4% avg upside
14 analysts
$148.00
39.14% Upside
 ·
GB:CTEC
ConvaTec
 Nov 22, 2022 BUY Strong Buy
+38.6% avg upside
17 analysts
$300.00
41.80% Upside
 ·
GB:0QBO
Coloplast A/S
 Feb 08, 2022 BUY Buy
+91.5% avg upside
17 analysts
$1150.00
203.14% Upside
 ·
FR:EMEIS
Orpea SA
 Jan 28, 2022 HOLD Buy
+458.4% avg upside
6 analysts
$43.00
196.64% Upside
 ·
GB:0M2O
Orion Corporation
 Aug 27, 2021 SELL Strong Sell
-54.6% avg upside
3 analysts
$28.70
58.93% Downside
 ·
GB:0GZK
Ion Beam Applications SA IBA
 Jan 20, 2020 SELL Strong Sell
1 analyst
 — ·
APNHY
Aspen Pharmacare
 Dec 05, 2019 HOLD Hold
2 analysts
 — ·
SE:MCOV.B
Medicover AB
 Nov 01, 2018 BUY Strong Buy
-59.3% avg upside
1 analyst
$93.00
59.30% Downside
 ·
RDY
Dr Reddy's Laboratories
 Nov 01, 2017 SELL Strong Sell
+54.1% avg upside
3 analysts
$30.50
98.27% Upside
 +5.7%
HKMPY
Hikma Pharmaceuticals
 Aug 21, 2017 HOLD Hold
2 analysts
 — ·
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
James Vane — Frequently Asked Questions
How accurate are James Vane's stock ratings?
Based on the calls 13Foresight could measure, about 75% of James's ratings were profitable over a one-year hold, with an average return of +81.8% per rating, or +92.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is James ranked on 13Foresight?
James Vane is currently ranked #24 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on DE:MRK, RGEDF, CH:NOVN, GB:OXB, ES:ROVI, CH:SFZN, CH:LONN, DE:SHL, DE:FRE, DE:FME, CH:SDZ, GB:HIK and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.